Enerflex (TSE:EFX – Free Report) had its target price raised by BMO Capital Markets from C$11.00 to C$15.00 in a report ...

Equifax (EFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On Friday, Equifax Inc (EFX) stock saw a decline, ending the day at $248.27 which represents a decrease of $-13.94 or -5.32% from the prior close of $262.21. The stock opened at $257.81 and touched a ...

RBC Capital analyst Keith Mackey maintained a Buy rating on Enerflex (EFX – Research Report) today and set a price target of $12.00. The ...

Enerflex (TSE:EFX – Free Report) had its target price increased by Acumen Capital from C$12.00 to C$15.00 in a research report released on Friday morning,BayStreet.CA reports. Several other brokerages ...

The use of AI-based digital pathology further corroborates the efficacy of EFX, with a high percentage of patients experiencing improvements in liver stiffness and fibrosis scores over a 96-week ...

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the ...

The study revealed that after 96 weeks of EFX treatment, over 40% of participants exhibited regression of liver fibrosis, a key indicator of MASH progression. This includes improvements in liver ...

SOUTH SAN FRANCISCO - Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company, announced significant clinical outcomes from its Phase 2b HARMONY study, evaluating the efficacy ...